Background Acute Kidney Injury (AKI) is a critical clinical syndrome with high morbidity and mortality, yet effective therapeutic agents are lacking. The Rheum-Salvia miltiorrhiza (R-S) combination, a traditional Chinese herbal pair, has been used to treat acute kidney injury, but its mechanisms remain unclear. Objective This study aimed to evaluate the nephroprotective effects of the R-S combination on cisplatin-induced AKI and to elucidate its underlying mechanisms through integrated multi-omics analyses. Methods Male C57BL/6 mice were randomly divided into five groups: Control group (Control), AKI model group (Model), Rheum - S. miltiorrhiza low-dose group (R-S-low), Rheum - S. miltiorrhiza high-dose group (R-S-high), and curcumin group (Cur). AKI was induced by a single intraperitoneal injection of cisplatin (15 mg/kg). After the experiment, renal function was assessed by measuring serum creatinine (Cr) and blood urea nitrogen (BUN). Inflammatory cytokines and oxidative stress markers were detected using ELISA. Histopathological changes of the kidney tissue were evaluated by HE staining. Gut microbiota composition, the cecal content metabolome and the renal transcriptome were further analyze. The MAPK signaling pathway in renal tissue was examined via RT-qPCR and Western blot. Results R-S treatment significantly improved renal function, lowering Cr and BUN, and attenuated renal histopathological injury. It also reduced oxidative stress and inflammation, elevating SOD and GSH, while decreasing IL-1β and TNF-α. Gut microbiota analysis showed that R-S restored microbial diversity, suppressed Escherichia-Shigella, and promoted LachnospiraceaeNK4A136group. Metabolomics identified 1237 differential metabolites, with enrichment in linoleic acid metabolism. Transcriptomics revealed 3530 differentially expressed genes, primarily associated with the MAPK signaling pathway. Molecular validation confirmed that R-S downregulated the mRNA expression of IL-1β, IL-6, TNF-α, MAPK 14, MAPK 8, NFKB 1, FOS, and JUN, and suppressed the phosphorylation of p38 MAPK, JNK, and NF-κB p65. Conclusion The R-S combination alleviates cisplatin-induced AKI by modulating the gut microbiota, regulating metabolic profiles, and suppressing the MAPK signaling axis. This study provides a holistic, multi-omics perspective on the mechanisms of R-S, supporting its potential as a therapeutic agent for AKI.
Zhang et al. (Wed,) studied this question.